Loading...

Forthal, Donald N.

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
CA 92697-3950
Phone(949) 824-3366
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection
    NIH/NIAID R01AI118581Jun 15, 2015 - May 31, 2020
    Role: Principal Investigator
    The impact of antibody and pH on female-to-male SIV infection
    NIH/NIAID R01AI102715Jul 6, 2012 - Jun 30, 2016
    Role: Principal Investigator
    Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
    NIH/NIAID R01AI090656Jun 14, 2010 - May 31, 2014
    Role: Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH/NIAID R33AI079775May 1, 2009 - Jul 31, 2014
    Role: Co-Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH/NIAID R21AI079775May 1, 2009 - Aug 15, 2011
    Role: Principal Investigator
    Protective immunity against HIV: the role of IgG subclass and glycosylation
    NIH/NIAID R21AI078477Mar 1, 2008 - Feb 28, 2011
    Role: Principal Investigator
    Fcy Receptor Polymorphisms and Risk of HIV Infection
    NIH/NIAID R21AI073147Jul 15, 2007 - Jun 30, 2009
    Role: Principal Investigator
    Novel Biological Activities of Anti-Viral Antibody
    NIH/NIAID R01AI052039Jun 1, 2002 - May 31, 2007
    Role: Principal Investigator
    IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION
    NIH/NIAID R03AI044610Jun 1, 1999 - May 31, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal D, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018 Jun; 24(6):847-856. PMID: 29785023.
      View in: PubMed
    2. Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal D, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol. 2018 01 15; 92(2). PMID: 29093095.
      View in: PubMed
    3. Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal D. Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathog. 2017 Dec; 13(12):e1006793. PMID: 29281723.
      View in: PubMed
    4. Huang Y, Ferrari G, Alter G, Forthal D, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME. Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol. 2016 12 15; 197(12):4603-4612. PMID: 27913647.
      View in: PubMed
    5. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal D, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 10 06; 22(10):1192. PMID: 27711066.
      View in: PubMed
    6. Gach JS, Venzon D, Vaccari M, Keele BF, Franchini G, Forthal D. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. J Virol. 2016 10 01; 90(19):8487-95. PMID: 27440881; PMCID: PMC5021405 [Available on 03/12/17].
    7. Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, Billings EA, Schwartz J, Prado I, Bobb K, Zhang W, Montefiori DC, Foulds KE, Ferrari G, Robert-Guroff M, Roederer M, Phan TB, Forthal D, Stablein DM, Phogat S, Venzon DJ, Fouts T, Franchini G. Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol. 2016 10 01; 197(7):2726-37. PMID: 27591322.
      View in: PubMed
    8. Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal D, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One. 2016; 11(8):e0160341. PMID: 27500639; PMCID: PMC4976892.
    9. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal D, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 07; 22(7):762-70. PMID: 27239761.
      View in: PubMed
    10. Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal D, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Apr; 90(8):4133-4149. PMID: 26865719.
      View in: PubMed
    11. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal D, Spearman P, Crowe JE. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol Immunol. 2016 Feb; 70:94-103. PMID: 26748387; PMCID: PMC4762738 [Available on 02/01/17].
    12. Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal D, Overbaugh J. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine. 2015 Oct; 2(10):1464-77. PMID: 26629541; PMCID: PMC4634620.
    13. Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal D, Altmann F, Steinkellner H, Mach L. Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A. 2015 Oct 13; 112(41):12675-80. PMID: 26417081; PMCID: PMC4611627.
    14. Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal D, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug; 11(8):e1005042. PMID: 26237403.
      View in: PubMed
    15. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal D, Spearman PW, Crowe JE. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. PLoS One. 2015; 10(7):e0133509. PMID: 26226263; PMCID: PMC4520566.
    16. Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal D, Felgner PL, Gach JS. A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One. 2015; 10(5):e0125581. PMID: 25938510; PMCID: PMC4418728.
    17. Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal D, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015 Apr 21; 33(17):2086-95. PMID: 25769884; PMCID: PMC4411954.
    18. Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauernfried S, Furtmüller PG, Forthal D, Mach L, Obinger C, Kunert R. Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta. 2015 Oct; 1854(10 Pt A):1536-44. PMID: 25748881; PMCID: PMC4582045.
    19. Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal D, Loret EP, Rasmussen RA, Ruprecht RM. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine. 2014 Nov 12; 32(48):6527-36. PMID: 25245933; PMCID: PMC4343195.
    20. Forthal D. Functions of Antibodies. Microbiol Spectr. 2014 Aug 15; 2(4):1-17. PMID: 25215264.
      View in: PubMed
    21. Forthal D. Functions of Antibodies. Microbiol Spectr. 2014 Aug; 2(4):AID-0019-2014. PMID: 26104200.
      View in: PubMed
    22. Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93. PMID: 24872518; PMCID: PMC4135905.
    23. Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal D. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. J Infect Dis. 2015 Jan 01; 211(1):45-52. PMID: 24850790.
      View in: PubMed
    24. Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal D, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology. 2014 Jan 20; 11:8. PMID: 24444350; PMCID: PMC3905655.
    25. Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal D, Katlama C, Jung BH, Murphy RL. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One. 2014; 9(1):e85371. PMID: 24454852; PMCID: PMC3893210.
    26. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal D. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 2013; 9(11):e1003776. PMID: 24278022; PMCID: PMC3836734.
    27. Forthal D, Hope TJ, Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS. 2013 Sep; 8(5):393-401. PMID: 23924999; PMCID: PMC4097845.
    28. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal D, Poignard P, Zwick MB. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One. 2013; 8(8):e72054. PMID: 23991039; PMCID: PMC3753353.
    29. Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal D, Hessell AJ, Haigwood NL. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol. 2013 Oct; 87(19):10447-59. PMID: 23885083; PMCID: PMC3807376.
    30. Gorlani A, Forthal D. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res. 2013 Jul; 11(5):421-6. PMID: 24191936.
      View in: PubMed
    31. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal D, Sattentau QJ, Villinger F, Corti D, Ruprecht RM. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013 Jun 01; 27(9):F13-20. PMID: 23775002; PMCID: PMC4084966.
    32. Forthal D, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):31-3. PMID: 23344546; PMCID: PMC3625514.
    33. Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013; 8(3):e58724. PMID: 23533588; PMCID: PMC3606348.
    34. Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal D, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol. 2013 Mar; 87(6):3538-48. PMID: 23325681; PMCID: PMC3592147.
    35. Forthal D, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fc? receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012 Oct 04; 120(14):2836-42. PMID: 22915639; PMCID: PMC3466964.
    36. Forthal D, Phan TB, Slepenkin AV, Landucci G, Chu H, Elofsson M, Peterson E. In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents. 2012 Oct; 40(4):354-60. PMID: 22819150; PMCID: PMC3438335.
    37. Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal D, Montefiori D, Abel K. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology. 2012 Jul 17; 9:57. PMID: 22805180; PMCID: PMC3419085.
    38. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal D, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc?RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012 Jun; 86(11):6189-96. PMID: 22457527; PMCID: PMC3372207.
    39. McBurney SP, Landucci G, Forthal D, Ross TM. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):1063-72. PMID: 22214267.
      View in: PubMed
    40. Rasmussen RA, Siddappa NB, Lakhashe SK, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-Guroff M, Montefiori DC, Forthal D, O'Connor D, Ruprecht RM. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS. 2012 Jan 14; 26(2):149-55. PMID: 21941166; PMCID: PMC3767758.
    41. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal D, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Jan 04; 482(7383):89-93. PMID: 22217938; PMCID: PMC3271177.
    42. Forthal D, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS. 2011 Nov 13; 25(17):2099-104. PMID: 21832933.
      View in: PubMed
    43. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal D, Franchini G. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine. 2011 Dec 09; 30(1):78-94. PMID: 22037204.
      View in: PubMed
    44. Forthal D, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. Fc-glycosylation influences Fc? receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010 Dec 01; 185(11):6876-82. PMID: 21041724.
      View in: PubMed
    45. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal D, Haigwood NL. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010 Oct; 16(10):1117-9. PMID: 20890292; PMCID: PMC2952052.
    46. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal D, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010 Apr 12; 207(4):763-76. PMID: 20368576; PMCID: PMC2856026.
    47. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal D, Koff WC, Poignard P, Watkins DI, Burton DR. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010 Feb; 84(3):1302-13. PMID: 19906907; PMCID: PMC2812338.
    48. Forthal D, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2009 Sep; 4(5):388-93. PMID: 20048702; PMCID: PMC2882066.
    49. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal D, Self SG, Carville A, Mansfield K, Goudsmit J. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009 Sep; 83(18):9584-90. PMID: 19553307; PMCID: PMC2738237.
    50. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal D, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. PMID: 19436712; PMCID: PMC2674935.
    51. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal D, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 01; 457(7225):87-91. PMID: 18997770; PMCID: PMC2614452.
    52. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal D, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. PMID: 18842730; PMCID: PMC2593361.
    53. Eastman D, Piantadosi A, Wu X, Forthal D, Landucci G, Kimata JT, Overbaugh J. Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J. 2008 Aug 04; 5:90. PMID: 18680596; PMCID: PMC2518139.
    54. Forthal D, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007 Dec 01; 179(11):7916-23. PMID: 18025239.
      View in: PubMed
    55. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal D, Parren PW, Marx PA, Burton DR. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 Sep 06; 449(7158):101-4. PMID: 17805298.
      View in: PubMed
    56. Forthal D, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007 May 15; 178(10):6596-603. PMID: 17475891.
      View in: PubMed
    57. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007 May; 81(10):5024-35. PMID: 17329327; PMCID: PMC1900210.
    58. Florese RH, Van Rompay KK, Aldrich K, Forthal D, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006 Sep 15; 177(6):4028-36. PMID: 16951366.
      View in: PubMed
    59. Forthal D, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006 Sep; 80(18):9217-25. PMID: 16940533; PMCID: PMC1563916.
    60. Van Rompay KK, Blackwood EJ, Landucci G, Forthal D, Marthas ML. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J. 2006 Apr 03; 3:22. PMID: 16584561; PMCID: PMC1500998.
    61. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal D, Leedom J, Leibowitz M, McCutchan JA, Richman DD. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18; 19(3):295-302. PMID: 15718840.
      View in: PubMed
    62. Forthal D, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005 Feb; 79(4):2042-9. PMID: 15681406; PMCID: PMC546539.
    63. Flynn NM, Forthal D, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 01; 191(5):654-65. PMID: 15688278.
      View in: PubMed
    64. Yasuda JM, Miller C, Currier JS, Forthal D, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther. 2004 Oct; 9(5):753-61. PMID: 15535413.
      View in: PubMed
    65. Becerra JC, Arthur JF, Landucci GR, Forthal D, Theuer CP. CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery. 2003 Apr; 133(4):404-10. PMID: 12717358.
      View in: PubMed
    66. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal D, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002 Oct 18; 16(15):F33-40. PMID: 12370520.
      View in: PubMed
    67. Forthal D, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001 Aug; 75(15):6953-61. PMID: 11435575; PMCID: PMC114423.
    68. Forthal D, Landucci G, Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):553-61. PMID: 11350669.
      View in: PubMed
    69. Forthal D, Phan T, Landucci G. Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells. Transpl Infect Dis. 2001; 3 Suppl 2:31-4. PMID: 11926747.
      View in: PubMed
    70. Forthal D, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999 Oct; 180(4):1338-41. PMID: 10479168.
      View in: PubMed
    71. Forthal D, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods. 1998 Nov 01; 220(1-2):129-38. PMID: 9839934.
      View in: PubMed